The business will revert to its original name, Syntagon AB, and is expected to strengthen Nanologica’s production capacity and contribute positively to group earnings already in 2026, the company states.

An independent, wholly owned subsidiary within the Nanologica group

Nanologica is acquiring all shares in the company, which will be run as an independent, wholly owned subsidiary within the Nanologica group. Syntagon, a small‑molecule API contract development and manufacturing organisation with just over 45 employees in Södertälje, generated around SEK 80 million in sales in 2025 and specialises in taking APIs from early lead molecules through clinical supply and into manufacturing. The current CEO, Annette Roos, will remain in her role, and operations will continue in the existing premises. The Syntagon name, well known in the Nordic market since the company’s founding in 1999, is being restored following several years under Ardena ownership.

Expands in‑house production and increases flexibility for medium‑sized, business‑critical orders

For Nanologica, whose core business is silica-based purification media for pharmaceutical manufacturing, the acquisition significantly expands in‑house production and increases flexibility for medium‑sized, business‑critical orders. Management expects annual cost synergies of SEK 4–5 million within 18 months through coordination of premises, production and administrative functions. Nanologica does not plan to inject additional capital into Syntagon, as the company is viewed as having sufficient working capital and is expected to return to positive operating cash flow in 2026 following recent commercial measures.

The purchase price will be settled in newly issued Nanologica shares at the same subscription price as an upcoming rights issue, potentially combined with a directed share issue. The seller, Ardena Sweden, is subject to an 18‑month lock‑up on these shares and has entered into a 15‑month take‑or‑pay commitment to source services from or refer business to Syntagon for approximately SEK 18 million, supporting utilisation of the site post‑transaction.

As part of the deal, Ardena CEO Jeremie Trochu will be proposed as a new member of Nanologica’s Board at an Extraordinary General Meeting in March, underscoring the parties’ intention to collaborate on joint customer projects while Ardena remains an important CDMO client of the Södertälje facility.

“The acquisition of Syntagon takes Nanologica to a whole new level and gives us the opportunity to accelerate the group’s development. Syntagon currently has a turnover of approximately SEK 80 million and we see that the business has very good opportunities to grow, among other things by directly adding resources in sales and business development. The acquisition also entails cost synergies, partly in the form of pure savings for premises rent, and partly savings through coordination of production and administrative functions,” says Nanologica’s CEO Andreas Bhagwani. “

For Nanologica’s part, the acquisition means that we will be able to provide customers with evaluation batches of different product types to a much greater extent, which is necessary to enable future business. The acquisition also gives us access to premises that are better suited to our current business and that provide us with an infrastructure to develop new products and a complement to our current contract producer of silica. We are already well acquainted with the operations through the cooperation we have had,” he adds.